Celgene Corporation to Announce First Quarter 2018 Results on May 04, 2018
Monday, April 09, 2018 7:30:00 AM ET
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) will host a conference call and live audio webcast on Friday, May 04, 2018 at 9 a.m. ET to discuss first quarter 2018 financial and operational results. The first quarter results will include the financial and operational results of Juno Therapeutics, Inc. following the March 6, 2018 close of the acquisition. The webcast can be accessed from the Investor Relations page at www.celgene.com .
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. For more information, please visit www.celgene.com . Follow Celgene on Social Media: @Celgene , Pinterest , LinkedIn , Facebook and YouTube .
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.
Hyperlinks are provided as a convenience and for informational purposes only. Celgene bears no responsibility for the security or content of external websites.
Patrick E. Flanigan III, 908-673-9969
Corporate VP, Investor Relations
Brian Gill, 908-673-9530
VP, Corporate Communications
Source: Celgene Corporation